Proactive therapeutic drug monitoring with Humira could help reduce the risk for treatment failure in patients with inflammatory bowel disease, according to results of a retrospective cohort.
Adam S. Cheifetz, MD, director of the center for IBD at Beth Israel Deaconess Medical Center and Harvard Medical School said research has demonstrated that therapeutic drug monitoring (TDM) is effective for optimizing anti-TNF therapy in patients with IBD, but most studies have focused on reactive testing of Remicade (infliximab, Janssen).
“We have previously shown that proactive TDM with infliximab

Source link